1	Running Title: Modeling to predict SARS-CoV-2 transmission dynamics
2	Keywords: SARS-CoV-2, COVID-19, cycle threshold, viral load, transmission, testing, public
3	health, vaccine, variant of concern
4	Prediction of SARS-CoV-2 transmission dynamics based on population-level cycle
5	threshold values: A Machine Learning and mechanistic modeling study
6	
7	Authors: Afraz A. Khan, MSc ¹ , Hind Sbihi, PhD ^{1,2} , Michael A. Irvine, PhD ^{1,2} , Agatha N.
8	Jassem, PhD ^{1,3} , Yayuk Joffres, MPH ^{1,2} , Braeden Klaver, MPH ^{1,2} , Naveed Janjua, MBBS,
9	DrPH ^{1,2} , Aamir Bharmal, MD, MPH ^{2,4} , Carmen H. Ng, MSc ⁴ , Amanda Wilmer, MD ⁵ , John
10	Galbraith, MD ⁶ , Marc G. Romney, MD ^{3,7} , Bonnie Henry, MD, MPH ⁸ , Linda M. N. Hoang, MD,
11	MSc ^{1,3} , Mel Krajden, MD ^{1,3} , Catherine A. Hogan, MD, MSc ^{1,3*}
12	Affiliations:
13	¹ British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
14	² School of Population and Public Health, University of British Columbia, Vancouver, British
15	Columbia, Canada
16	³ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver,
17	British Columbia, Canada
18	⁴ Office of the Medical Health Officer, Fraser Health, Surrey, British Columbia, Canada
19	⁵ Division of Medical Microbiology, Kelowna General Hospital, Kelowna, British Columbia,
20	Canada
21	⁶ Division of Microbiology and Molecular Diagnostics, Victoria General Hospital, Victoria,
22	British Columbia, Canada

- 23 ⁷Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, British
- 24 Columbia, Canada
- 25 ⁸Ministry of Health, Victoria, British Columbia, Canada
- 26

27 *Corresponding author

- 28 Address for correspondence:
- 29 Catherine A. Hogan
- 30 655 W 12th Avenue, Room 2054
- 31 Vancouver, BC, Canada, V6R 2M7
- 32 Phone (604) 802-5183
- 33 <u>catherine.hogan@bccdc.ca</u>

34 Abstract (169 words)

35	Background: Polymerase chain reaction (PCR) cycle threshold (Ct) values can be used to
36	estimate the viral burden of Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-
37	CoV-2) and predict population-level epidemic trends. We investigated the use of machine
38	learning (ML) and epidemic transmission modeling based on Ct value distribution for SARS-
39	CoV-2 incidence prediction during an Omicron-predominant period.
40	Methods: Using simulated data, we developed a ML model to predict the reproductive number
41	based on Ct value distribution, and validated it on out-of-sample province-level data. We also
42	developed an epidemiological model and fitted it to province-level data to accurately predict
43	incidence.
44	Results: Based on simulated data, the ML model predicted the reproductive number with highest
45	performance on out-of-sample province-level data. The epidemiological model was validated on
46	outbreak data, and fitted to province-level data, and accurately predicted incidence.
47	Conclusions: These modeling approaches can complement traditional surveillance, especially
48	when diagnostic testing practices change over time. The models can be tailored to different
49	epidemiological settings and used in real time to guide public health interventions.
50	
51	Funding: This work was supported by funding from Genome BC, Michael Smith Foundation for
52	Health Research and British Columbia Centre for Disease Control Foundation to C.A.H. This
53	work was also funded by the Public Health Agency of Canada COVID-19 Immunity Task Force
54	COVID-19 Hot Spots Competition Grant (2021-HQ-000120) to M.G.R.

55 Introduction

56 SARS-CoV-2 viral burden can be quantitated by the use of polymerase chain reaction (PCR) 57 cycle threshold (Ct) values, which are inversely proportional to the amount of target viral 58 sequence present in the patient sample. Although this information is frequently available from 59 routine molecular methods for the diagnosis of SARS-CoV-2 infection, clinical results are almost universally reported qualitatively as present or absent due to sources of sampling 60 61 variability, lack of inter-test standardization, insufficient supporting clinical correlation data, and 62 lack of regulatory approval for purposes other than qualitative reporting, all of which limit 63 interpretation of Ct values for clinical care. Though the use of Ct values to guide individual-level 64 management is not currently routinely recommended (1, 2), the assessment of aggregated Ct 65 values at a population level may be useful to help assess early epidemiological transmission 66 trends to improve epidemic forecasting (3-5), and parallels the concept of measuring community 67 viral load used for other viruses (6-8). Accurate projection of epidemic trends is critical to 68 effectively plan public health efforts including healthcare resource allocation. Indeed, an 69 epidemic in the growth phase is more likely to be associated with high viral load burden at a 70 population level; conversely, the decline phase of an epidemic is likely to demonstrate lower 71 viral burden. A modeling approach was previously published to inform epidemic SARS-CoV-2 72 trajectory based on aggregated Ct value data (3), and supported the usefulness of population-73 level Ct value analysis. However, SARS-CoV-2 testing practices globally have evolved 74 substantially during the pandemic, most frequently by restricting testing to symptomatic 75 individuals, which limits the usefulness of modeling approaches that rely on stable population 76 sampling strategies. Starting in December 2021 in British Columbia (BC), use of PCR testing 77 was partially restricted in the context of roll-out of rapid antigen tests, limiting understanding of

78 population trends. New tools are needed to estimate incidence in a manner that is independent of 79 the biases associated with testing guidance. This includes modeling approaches robust to varying 80 testing guidelines, sample selection strategies and epidemiologic settings, and that account for 81 other variables that impact viral burden such as variant of concern (VoC) and vaccination status. 82 The main variants of concern (VoC) described to date have been associated with varying impact 83 on viral burden, with the Delta and certain Omicron subvariants associated with highest viral 84 load (9-14). Furthermore, evidence suggests that SARS-CoV-2 vaccination is associated with a 85 reduction in viral burden, and correspondingly higher Ct values and potentially lower 86 transmission risk, in individuals who develop post-vaccination infection (14-19). In this study, 87 we investigated two modeling approaches based on Ct value distribution of asymptomatic 88 individuals, machine learning and epidemic transmission modeling, to predict SARS-CoV-2 89 incidence based on province-wide data and an outbreak in a long-term care facility in British 90 Columbia, Canada. We assessed the novel application of five machine learning models (Lasso, 91 LGBM, XGBoost, CatBoost, RF), and validated two previously-described epidemic models 92 (SEIR) (3), to determine the highest performing models across a range of epidemiological 93 settings to predict SARS-CoV-2 incidence.

94

95 Methods

96 Study design

Individuals with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection by
nasopharyngeal swab or saline gargle between November 19th 2021 and January 8th 2022 were
included, capturing emergence of Omicron wave in the province. Descriptive analyses of Ct
value distribution included the two main specimen type categories: nasopharyngeal swabs and

101	saline gargles, while modeling analyses focused on nasopharyngeal swabs given the higher
102	diagnostic yield and collection standardization. Analysis was based on province-wide data
103	incorporating all SARS-CoV-2 diagnostic tests based on the E gene target performed in BC.
104	Three pandemic phases in BC were considered based on vaccination roll-out and VoC
105	distribution (Supplemental Table 1). To capture the largest representation of asymptomatic
106	individuals in BC throughout the pandemic, the study focused on phase 3. These individuals
107	were tested in the context of occupational screening or pre-travel. The study population sampled
108	thus represented a heterogeneous mix of vaccinated and unvaccinated individuals, and
109	predominantly Omicron (BA.1) variant (Figures 1A and 1B).
110	
111	Given the importance of population composition in informing model selection, the selected
112	models were chosen based on several factors including sampling type and frequency, sample
113	size, and computational complexity. Current models which make use of cross-sectional Ct values
114	to infer epidemic trajectories (3) rely on random sampling of the population to accurately predict
115	epidemic trends. However, in the context of symptom-based testing, the distribution of Ct values
116	is not a complete representation of the infected population. Thus, this study was performed on a
117	population of asymptomatic individuals as they served as the best proxy for frequent non-
118	symptom-based sampling.
119	
120	Testing practices and public health measures
121	COVID-19 diagnostic testing and laboratory test guidelines changed in BC over the course of the
122	pandemic, and can be summarized as follows: 1) exposure-based testing (onset of the pandemic),

123 2) targeted testing (starting March 16, 2020), 3) expanded testing (starting April 9, 2020), 4)

124	symptom-based testing (starting April 21, 2020), 5) revised symptom-based testing (starting
125	December 17, 2020), and 6) High risk/targeted population testing (increased risk of severe
126	disease or work in a high-risk setting) (starting January 18, 2021) (20, 21). Thus, asymptomatic
127	and mildly symptomatic testing was initiated starting in December 2021 with the organized roll-
128	out of rapid antigen tests, which corresponds with the current study. While COVID-19 testing
129	was initially centralized at the BCCDC Public Health Laboratory (PHL), testing capacity and
130	data capture reflects results from all provincial testing laboratories which generate E gene Ct
131	values.

132

133 Laboratory data - SARS-CoV-2 diagnostic testing

134 SARS-CoV-2 diagnostic testing was performed in laboratories throughout all five health

135 authorities in BC, and only assays based on the *E* gene target were included for this study. The

136 testing strategy and test result interpretation criteria used for the participating laboratories are

137 described separately (Supplemental Table 2), and included the BCCDC PHL laboratory-

138 developed test (LDT) (22), LightMix SarbecoV E-gene plus EAV control assay (TIB Molbiol,

139 Berlin, Germany), Alinity m SARS-CoV-2 (Abbott, Chicago, IL), BD SARS-CoV-2 (Becton,

140 Dickinson and Co., Franklin Lakes, NJ), cobas 6800 and 8800 (Roche Diagnostics, Basel

141 Switzerland), GeneXpert Xpress SARS-CoV-2 (Cepheid, Sunnyvale, CA), Panther Fusion

142 (Hologic, San Diego, CA) and Allplex SARS-CoV-2 (Seegene, Seoul, South Korea). For

143 individuals having undergone repeat SARS-CoV-2 testing within a one-week period, only the

144 first positive test per person was included.

145

146 Laboratory data - Variant of Concern identification

147 The BCCDC Public Health Laboratory (PHL) continuously monitors for variants of concern 148 (VOCs), variants of interest (VOIs), and variants under monitoring (VUMs). Various approaches 149 were used over time including VoC screening and confirmation by whole genome sequencing 150 (WGS) when applicable at the BCCDC PHL as previously described (22). Testing strategy is 151 optimized based on available capacity and clinical and public health needs, and changed over the 152 course of the SARS-CoV-2 pandemic. One such strategy included deployment of in brief, a 153 subset of samples in the earlier phase of the epidemic (January 2021 to May 2021) was tested by targeted single nucleotide polymorphism (SNP) quantitative polymerase chain reaction (qPCR) 154 155 for VoC screening, followed by confirmation by WGS. From June 2021 onward, sample VoC 156 status was detected by WGS alone. From September 2021, owing to increased case burden and 157 limited capacity, there was a transition from WGS of all samples to a subset positive SARS-158 CoV-2 samples. This subset comprised of targeted surveillance (cases from outbreaks, vaccine 159 escape, reinfection and travel-related), and representative baseline surveillance. In addition, 160 100% of positive samples underwent WGS in the first week of each month. Starting November 161 15 2021 in the context of the Omicron variant emergence, WGS was resumed for all samples. 162 Owing to the high transmissibility of Omicron and the surge in case load, starting December 21 163 2021, there was transition from full sequencing to sequencing a subset of representative positive 164 samples in addition to priority cases (including outbreaks, long-term care, vaccine escape, travelrelated, hospitalization)). Full VoC characterization for the province of BC is described 165 166 separately (Supplemental Figure 2).

167

168 Vaccination status

169 Vaccination status was defined based on the date of vaccine receipt relative to the date of the 170 sample collection included for the study (Supplemental Figure 3) (23). For primary dose series 171 all mRNA (Pfizer, Moderna) and viral vector vaccines (AstraZeneca, Janssen) were considered. 172 For the Janssen vaccine only, fully vaccinated status was defined as having received one dose 14 173 days or more prior to sample collection. For all other vaccines, Unvaccinated status was defined 174 as having received no SARS-CoV-2 vaccine, or having received a SARS-CoV-2 vaccine less 175 than 21 days prior to the sample collection date. Partially vaccinated status was defined as 176 having received the SARS-CoV-2 vaccine dose 1 greater or equal to 21 days prior to sample 177 collection, but having received dose 2 less than 14 days prior to the sample collection. Fully 178 vaccinated status was defined as greater or equal to 14 days since the receipt of dose 2, but 179 having received dose 3 less than 14 days prior to the sample collection. Cross-over vaccination 180 was considered in the same category as homologous vaccine schedules.

181

182 **Outbreak case study**

183 To further validate the models, a separate analysis was performed using a well-characterized 184 outbreak in a long-term care facility that occurred in BC. This outbreak was selected on the 185 basis of time of occurrence of pre-vaccination roll-out to the general population, large size and 186 generalizability of the affected population. This outbreak included large-scale asymptomatic 187 testing. Testing was done weekly until no additional cases were identified within 14 days of the 188 last exposure. There were 7 rounds of weekly testing at the outbreak facility, all negative 189 residents and staff were tested for each round. Anyone who developed symptoms was also tested. 190 The epidemiologic data and curve describing the outbreak are presented separately 191 (Supplemental Figure 4). As for the main study, analysis was based on SARS-CoV-2

diagnostic tests based on the *E* gene target. However, due to missing data in the long-term care
facility data, wherever the *E* gene target was unavailable the *ORF1* gene target was used instead.

195 Data sources

196 Two main data sources were employed for this study: 1) the Provincial Health Laboratory

197 Viewer and Reporter (PLOVER) database which includes the laboratory diagnostic datasets, and

198 2) the Provincial Immunization Registry (PIR) dataset which includes vaccination data. The

199 laboratory datasets house data on SARS-CoV-2 testing (including date of collection, specimen

200 type, diagnostic quantitative PCR gene target results, VoC screening, and SARS-CoV-2 lineage

201 based on WGS), and individual-level epidemiological data (including age, sex, patient as well as

202 ordering physician health authority). Gene target results include Ct values of the *E* and ORF1

203 targets, and the internal control RNAseP. The PIR dataset includes individual-level vaccination

204 data (including number, type, series, dose and date of each vaccine received). Both of these

205 datasets form the basis of the covariates which inform the ML models in the study. For the

206 outbreak case study, additional data were directly gathered from public health partners

207 (Supplemental Figure 4) as these were not otherwise available through provincial datasets. Data

208 linkages were performed between the laboratory and PIR datasets through a sequential

209 deterministic linkage based on a minimum of three personal identifiers (personal health number,

210 last name with first three digits of first name, and date of birth). These linkages were performed

prospectively on a weekly basis, and specimens with unsuccessful linkages were excluded fromthe study.

213

214 Data & Code Availability

215	The genomic sequencing data are publicly available in GISAID under the submitter British
216	Columbia Center for Disease Control Public Health Laboratory (BCCDC PHL). The individual
217	level demographic and epidemiological data can be made accessible following the data
218	governance and data access policy guidelines (http://www.bccdc.ca/about/accountability/data-
219	access-requests). Code for this study is available (https://github.com/Afraz496/Vital-E-paper).
220	
221	Ethics
222	This research was approved by University of British Columbia Research Ethics (H20-0297
223	BCC19C-COVID-19 Research).
224 225	Models
226	Machine learning and epidemic transmission models
227	This study compared two different approaches for inference, machine learning (ML) and
228	epidemic transmission modeling, both of which were used to predict the reproductive number
229	(\mathbf{R}_t) to estimate incidence. The first modeling approach was based on a collection of ML
230	approaches, including Lasso (24), Random Forest (RF), Light Gradient Boosting Modeling
231	(LGBM), eXtreme Gradient Boosted Modeling (XGBM) and CatBoost. Due to the testing
232	guidelines which were tailored for mainly symptomatic individuals, and given the absence of
233	sufficiently-large random samples, analysis was pursued with simulated data instead. Ct data
234	were generated to simulate a sufficiently large random sample of a population using the
235	virosolver package (R software, version 4.1.2). This was applied on varying sample sizes (100,
236	1000 and 10000) on a simulated population of 50,000 individuals. The simulation horizon was
237	set at 140 calendar days to encompass a typical single COVID-19 wave. These data were used to
238	create summary statistics of the Ct distribution including mean, median, variance, skewness and

239 kurtosis. The trained data was generated from a unique simulation file with a fixed random seed 240 and three distinct sample sizes, so three models were investigated in this study. Hyperparameter 241 tuning was performed via a grid search of hyperparameters on each model (Supplemental Table 242 5). The best performing model was chosen by finding the optimal set of hyperparameters for 243 which the Mean squared error (MSE) between the true simulated Rt and Predicted simulated Rt 244 was minimized. SHapley Additive exPlanation (SHAP) analysis was performed for feature 245 ranking and importance (25). The second modeling approach was adapted from an existing 246 methodology (3), and is based on a single epidemic model. The compartmental SEIR model 247 captures different stages in individual infections (namely Susceptible, Exposed, Infectious and 248 Recovered). The SEIR model was validated on a patient outbreak facility in BC where point 249 prevalence testing was done in infrequent intervals. The SEIR model was then fitted to 250 provincial data from asymptomatic individuals. Modifications to the viral kinetics for the SEIR 251 model were applied to these provincial data to account for the specific nature of the Omicron 252 (BA.1) variant.

253

254 Results

255 Cohort description

During the study period, a total of 331,785 SARS-CoV-2 tests were performed in BC, of which

257 79,443 were positive. Restricting these to the first positive test per person, there were 71,642

included in the study (Figures 1A and 1B). Of these, 35,369 were nasopharyngeal specimens

- and 36,108 were saline gargle specimens (Table 1 and Figure 2). The cohort was predominantly
- composed of adults aged 18-59 years (72.2%), followed by adults aged 60 years and above
- 261 (12.1%), and children 0-17 years (15.7%). Over half the cases resided in two of the five health
- authorities accounting for 35.9% and 30.9%, respectively. The Omicron (BA.1) variant

- 263 predominated throughout the study (**Table 1 and Supplemental Figure 2**). By the end of the
- study period, a total of 18,459 (27.3%) were unvaccinated, 1,540 (2.3%) had received 1 dose of
- 265 vaccine, and 47,580 (70%) were fully vaccinated.
- 266

267 First modeling approach: machine learning

268 The fitted ML models were applied to out-of-sample Ct data from the simulated Ct values

269 (Figure 3). With increasing sample sizes, the MSE across each model reduced by 82% showing

an increased ability in higher moments (mean, median, variance, skewness and kurtosis) of the

271 Ct distribution to predict epidemic trends. Random Forest showed the largest improvement in

272 MSE performance while demonstrating lowest performance in smaller sample size. Besides the

smallest sample size, all models generally perform similarly across an increased sample size

274 (Figure 3). For the largest sample size, apart from Lasso all other models have a much tighter

275 IQR and smaller MSE median score (at around 0.03). Across all sample sizes, the variance of the

- 276 Ct distribution was the top ranking feature (Supplemental Figure 5).
- 277

278 Second modeling approach: epidemic transmission models

279 **SEIR**

280 The most precise results were observed with sampling from a total of five horizons. The model

281 posteriors indicated an incidence peak from December 27 2021 to January 1 2022, which

overlapped with the observed peak of reported cases in the province (Figure 4). Similarly, the

- 283 exponential growth phase coincided with the increase in reported cases from our cohort from
- 284 December 20 2021 to December 27 2021, and the decline of the incidence coincided with the
- decline in cohort cases from January 1 2022 to January 5 2022. The posterior predictive Ct

distribution also closely matched the observed Ct distribution on each of the time horizons,

supporting accurate incidence projection independent of biases of testing guidance.

288 Outbreak case study

289 This outbreak occurred in a long-term care facility, and resulted in a total of 156 individuals (93

residents and 63 staff) infected with SARS-CoV-2 (Supplemental Figure 4). Of these

291 individuals, 58.1% of infections were asymptomatic in the residents, whereas 9.5% were

asymptomatic within the staff. There were 26 (28.0%) deaths in the residents group, and no

293 deaths among the staff. A multiple cross-section SEIR model was fitted to the outbreak data, and

showed a peak in incidence on the 12th day of the outbreak which preceded by two days the

295 observed peak at the outbreak facility (Figure 5). The real incidence fell within the 95% credible

interval of the predicted MCMC chains of the SEIR model. The model also accurately predicted

the decline in cases by the 20th day of the outbreak (Figure 5).

298

299 Discussion

300 In this study, we demonstrated the utility of two distinct modeling approaches based on 301 aggregated cycle threshold values, machine learning and epidemic transmission modeling, to 302 predict epidemic trends across varying sampled patient populations, random, and targeted and 303 non-random testing. Based on out-of-sample mean squared error (MSE) change in the 304 reproduction number between the true and predicted values, the ML model performed best on 305 randomly-sampled province-level data. Within epidemic transmission models, the SEIR model 306 performed highest with randomly-sampled outbreak data. Taken together, these approaches 307 accurately predicted epidemic transmission dynamics at the outbreak case study level, and at a 308 provincial level for the province of BC, Canada. Early in the pandemic, SARS-CoV-2 diagnostic

309 molecular testing was more largely based on random sampling which, despite possible 310 underascertainment due to lack in testing access, could be used to estimate full case counts to 311 monitor and predict transmission dynamics. As testing needs overwhelmed laboratory capacity 312 with increasing case burden and the emergence of variants of concern, molecular testing practice 313 recommendations shifted to testing individuals who were symptomatic and/or with a minimal 314 illness severity, resulting in sampling of a selected population. These changes in testing 315 indications, foremost predicated on symptom-based testing, led to substantially more limited 316 capacity to assess case counts for epidemic monitoring, generating a critical unmet need for other 317 approaches to infer epidemic trends to support clinical and public health planning. 318 319 This study comprehensively investigated varying sampling types and modeling approaches, 320 drawing on both previously-published work and description of the novel application of machine 321 learning modeling for SARS-CoV-2 transmission dynamics prediction. Our work identified that 322 diagnostic testing indication, sampling type, and the individual population tested are critical 323 factors, and that model selection must be tailored to the epidemiological circumstances of 324 testing. More specifically, random vs targeted or non-random sampling must be accounted for to 325 ensure appropriate model selection, as SEIR modeling was only suitable for random sampling. 326 For example, performance of the SEIR model in this study was robust across sample sizes and 327 the long-term care facility dataset. Results from this modeling approach demonstrated a slight 328 difference in incidence peak timing and amplitude. This is likely explained due to the lag time 329 between onset of the infectious period and reporting given that site-wide facility testing was 330 performed at set time periods rather than on a daily basis, and represents a pragmatic approach to 331 real-world settings. Thus, this approach is well suited for long-term care or assisted living or

community-living facility outbreak investigations such as shelters, or within small hospital
systems. In contrast, the novel application of machine learning approaches described in this
study performed the best with large datasets (>1,000 COVID-19 positive cases), making this the
approach of choice for large population settings such as at the province, state or large hospital
network system level. Indeed, machine learning models can offer greater flexibility by
incorporating different summary statistics and other data as features, fully harnessing the
potential of larger datasets.

339

340 Importantly, all approaches described in this study could predict future trends within a one to 341 four-week timeframe, demonstrating utility for timely prediction of SARS-CoV-2 transmission 342 dynamics that could be harnessed to help inform future outbreak resource allocation and 343 decision-making. Thus, use of these models can be used to support critical decision-making 344 across several settings, including hospitals, long-term care facilities, public health departments 345 and others, to help inform planning of resource allocation, vaccination efforts, and isolation 346 practices. More specifically, this approach lays the groundwork for a sentinel surveillance 347 monitoring strategy that could be automated and alert appropriate authorities at pre-determined 348 signals of predicted incidence changes, and may be expanded to other infections for which 349 testing is widespread and predictive tools are needed.

350

This study focused on a time period of Omicron (BA.1) predominance, and revealed that despite its shorter incubation period compared to other variants of concern, the Ct distribution of this variant could successfully be described through an SEIR compartmental model and machine learning approaches. Furthermore, in the context of a sampled population with heterogeneous

vaccination status, the current study demonstrated accurate prediction of incidence based on overall Ct distribution and viral kinetics without incorporating individual-level vaccination status. Further work is necessary to study the impact of vaccination status on accuracy of incidence prediction.

359

360 The main strength of this study is that it provides a comprehensive modeling toolkit that can be 361 leveraged across population and sampling settings, and that may incorporate covariates such as 362 variant of concern and vaccination status. This approach could predict transmission dynamics in 363 a way that could not be performed through case count analysis from biased sampling as was 364 occurring in the province of BC. This modeling is also advantageous as it can be performed in 365 real-time, rather than rely on monitoring of clinical indicators of severity such as hospitalization 366 and intensive care unit admission which considerably lag behind true incidence rise. A limitation 367 of previous studies is the use of a single or limited methodology for analysis that may perform 368 well in a specific setting such as long-term care facilities, but lacked flexibility and predictive 369 performance for generalizability to larger settings and in the context of changing testing practices 370 (3). Our body of work filled this gap and further presented a methodology to incorporate 371 assessment of variant of concern and vaccination status, two important potential confounders on 372 Ct value distribution, although these characteristics were noted to be less important than the 373 moments of infection (mean, median, variance, skewness and kurtosis of the aggregated Ct 374 distribution). Additional strengths of this study also include the independent assessment of the 375 models in a long-term care facility outbreak to validate the previously-published models (3). 376 Furthermore, the main analysis drew on a provincial dataset linking laboratory data and 377 vaccination status in real-time, thus leveraging the design for the highest possible public health

378 uptake and impact. Taken together, this approach lays the framework for expansion to use for 379 other pathogens for which surveillance needs are critical including other respiratory pathogens 380 and monkeypox. Indeed, further work may also build on this approach and further integrate 381 complementary datasets including wastewater Ct distribution to further enhance prediction 382 ability.

383

384 However, there are several limitations. Firstly, the methodology is based on the assumption of 385 random or random sampling which is challenging to confirm. Indeed, testing practices were 386 modified following clinical and public health guidance of the province, and may have led to bias 387 in sampling. Restriction of the study population to the asymptomatic subgroup consisting of 388 travelers and occupational health testing led to greater confidence in the employed sampling 389 strategy tested and the validity of this assumption. The need for random sampling remains a 390 limitation for broader uptake of this approach, though it may be more attainable in the context of 391 outbreak investigation where full populations are sampled at once. Nonetheless, even when a full 392 population is sampled there may be specific population-level characteristics that need to be 393 accounted for. One such limitation in the current work is that although the long-term care 394 environment provides more a consistent testing environment, it tends to be a highly vaccinated 395 population which may introduce bias. Finally, this study aggregated Ct-level data across multiple 396 laboratories and assays, which may not adequately capture intra- and inter-assay variation. 397

In summary, this study proposes a comprehensive suite of modeling strategies based on
population-level Ct values to accurately predict SARS-CoV-2 transmission dynamics across
epidemiological settings. These modeling approaches can be used in real time to guide clinical

and public health interventions. Such tools are needed to estimate incidence in a manner that is
independent of the biases associated with testing guidance, and to complement traditional
surveillance based on case numbers or clinical indicators. Further work will be needed to expand
validation of the machine learning models based on larger datasets and different settings with
newly-emerging variants, to assess real-time predictive power for direct clinical and public
health impact.

407

408

409 Funding: This work was supported by funding by Genome BC, Michael Smith Foundation for
410 Health Research and British Columbia Centre for Disease Control Foundation to C.A.H. This
411 work was also funded by the Public Health Agency of Canada *COVID-19 Immunity Task Force*412 *COVID-19 Hot Spots Competition Grant (2021-HQ-000120)* to M.G.R.

413 Acknowledgments: We thank the laboratory teams (virology, bacteriology and molecular) at the 414 BCCDC Public Health Laboratory for their contribution toward testing, on which this research is 415 based. We also thank the data analytics team for supporting the data infrastructure and review 416 that enabled this work. Finally, we thank the British Columbia Association of Medical 417 Microbiologists for testing and sharing samples and data that enabled province-wide data 418 collection, and public health partners throughout the province for their dedicated effort to 419 outbreak management and infection control, and for sharing outbreak-level data that supported 420 this research.

421		
422		References
423		
424	1.	Infectious Diseases Society of America and Association of Molecular Pathology. 2021.
425		IDSA and AMP joint statement on the use of SARS-CoV-2 PCR cycle threshold (Ct)
426		values for clinical decision-making. <u>https://www.idsociety.org/globalassets/idsa/public-</u>
427	•	health/covid-19/idsa-amp-statement.pdf. Accessed August 19 2022.
428	2.	American Association for Clinical Chemistry. 2021. AACC Recommendation for
429		Reporting SARS-Cov-2 Cycle Threshold (CT) Values. <u>https://www.aacc.org/science-</u>
430		and-research/covid-19-resources/statements-on-covid-19-testing/aacc-recommendation-
431	2	tor-reporting-sars-cov-2-cycle-threshold-ct-values. Accessed August 19 2022.
432	3.	Hay JA, Kennedy-Shaffer L, Kanjilal S, Lennon NJ, Gabriel SB, Lipsitch M, Mina MJ.
433		2021. Estimating epidemiologic dynamics from cross-sectional viral load distributions.
434		medRxiv doi:10.1101/2020.10.08.20204222:2020.10.08.20204222.
435	4.	Walker AS, Pritchard E, House I, Kobotham JV, Birrell PJ, Bell I, Bell JI, Newton JN,
436		Farrar J, Diamond I, Studiey R, Hay J, Vinta KD, Peto TE, Stoesser N, Matthews PC,
43/		Eyre DW, Pouwels KB, team C-IS. 2021. Ct threshold values, a proxy for viral load in
438		community SARS-CoV-2 cases, demonstrate wide variation across populations and over
439	~	time. Elite 10. $\mathbb{N}^{(1)}$
440	э.	Phillips MC, Quintero D, Wald-Dickler N, Holtom P, Butler-Wu SM. 2022. SARS-Cov-
441		2 cycle threshold (Ct) values predict future COVID-19 cases. J Clin Virol 150-
442	6	151:105155. Harberts I. Tanzan F. 2016. Community wind lood on an index of HIV transmission.
443	0.	netertial Lenget HUV 2:0152 4
444	7	potential. Lancel HIV 5:0152-4.
445	/.	Das M, Chu PL, Santos GM, Scheef S, Viungholf E, McFarland W, Collax GN. 2010.
440		in San Francisco. PL oS One 5:011068
447	0	In San Francisco. FLos One 5.e11008. Jordan AF, Darlman DC, Claland CM, Wuka K, Sahaakman BP, Nash D, 2020
440	0.	Community viral load and henetitis C virus infection: Community viral load measures to
449		aid public health treatment efforts and program evaluation. I Clin Virol 124:104285
451	9	Wang V Chen R Hu F Lan V Vang 7 7han C Shi L Deng X Jiang M 7hong S Liao
452).	B Deng K Tang I Guo I Jiang M Fan O Li M Liu I Shi V Deng X Xiao X Kang
453		M Li V Guan W Li V Li S Li F Zhong N Tang X 2021 Transmission viral kinetics
454		and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou
455		China EClinicalMedicine 40:101129
456	10.	Tevssou E. Delagreverie H. Visseaux B. Lambert-Niclot S. Brichler S. Ferre V. Marot S.
457	10.	Jarv A. Todesco E. Schnuriger A. Ghidaoui E. Abdi B. Akhavan S. Houhou-Fidouh N.
458		Charpentier C. Morand-Joubert L. Boutolleau D. Descamps D. Calvez V. Marcelin AG.
459		Soulie C. 2021. The Delta SARS-CoV-2 variant has a higher viral load than the Beta and
460		the historical variants in nasopharyngeal samples from newly diagnosed COVID-19
461		patients. J Infect 83:e1-e3.
462	11.	Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L. Toh M. Lim YD. Lee PH. Lee TH.
463	-	Chia PY, Maurer-Stroh S, Lin RTP, Leo YS. Lee VJ. Lve DC. Young BE. 2021. Clinical
464		and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study
465		comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). Clin Infect Dis
466		doi:10.1093/cid/ciab721.

467	12.	King KL, Wilson S, Napolitano JM, Sell KJ, Rennert L, Parkinson CL, Dean D. 2022.
468		SARS-CoV-2 variants of concern Alpha and Delta show increased viral load in saliva.
469		PLoS One 17:e0267750.
470	13.	Ito K, Piantham C, Nishiura H. 2022. Relative instantaneous reproduction number of
471		Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark. J Med Virol
472		94:2265-2268.
473	14.	Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C, Iten A, Jacquerioz F, Kaiser L,
474		Vetter P. Eckerle I. Mever B. 2022. Infectious viral load in unvaccinated and vaccinated
475		individuals infected with ancestral. Delta or Omicron SARS-CoV-2. Nat Med 28:1491-
476		1500.
477	15.	Adamson PC, Pfeffer MA, Arboleda VA, Garner OB, de St Maurice A, von Bredow B.
478		Flint I. Kruglvak L. Currier IS. 2021. Lower Severe Acute Respiratory Syndrome
479		Coronavirus 2 Viral Shedding Following Coronavirus Disease 2019 Vaccination Among
480		Healthcare Workers in Los Angeles California Open Forum Infect Dis 8:0fab526
481	16	Brown CM Vostok I Johnson H Burns M Gharnure R Sami S Sabo RT Hall N
482	10.	Foreman A Schubert PL Gallagher GR Fink T Madoff LC Gabriel SB MacInnis B
483		Park DI Siddle KI Harik V Arvidson D Brock-Fisher T Dunn M Kearns A Laney
484		AS 2021 Outbreak of SARS-CoV-2 Infections Including COVID-19 Vaccine
485		Breakthrough Infections Associated with Large Public Gatherings - Barnstable County
486		Massachusetts July 2021 MMWR Morb Mortal Wkly Rep 70:1059-1062
487	17.	Regev-Yochay G. Amit S. Bergwerk M. Linsitch M. Leshem E. Kahn R. Lustig Y.
488	- , .	Cohen C. Doolman R. Ziy A. Novikov I. Rubin C. Gimpelevich I. Huppert A. Rahay G.
489		Afek A. Kreiss Y. 2021. Decreased infectivity following BNT162b2 vaccination: A
490		prospective cohort study in Israel. Lancet Reg Health Eur 7:100150.
491	18.	Levine-Tiefenbrun M. Yelin I. Alapi H. Katz R. Herzel E. Kuint J. Chodick G. Gazit S.
492		Patalon T. Kishony R. 2021. Viral loads of Delta-variant SARS-CoV-2 breakthrough
493		infections after vaccination and booster with BNT162b2. Nat Med 27:2108-2110.
494	19.	Jung J. Kim JY. Park H. Park S. Lim JS. Lim SY. Bae S. Lim YJ. Kim EO. Kim J. Park
495	-	MS, Kim SH. 2022. Transmission and Infectious SARS-CoV-2 Shedding Kinetics in
496		Vaccinated and Unvaccinated Individuals. JAMA Netw Open 5:e2213606.
497	20.	British Columbia Ministry of Health. 2022. B.C. COVID-19.
498		https://experience.arcgis.com/experience/a6f23959a8b14bfa989e3cda29297ded.
499		Accessed September 23 2022.
500	21.	British Columbia Centre for Disease Control BCMoH. 2020. Summary of evidence for
501		updated COVID-19 testing guidance in British Columbia. http://www.bccdc.ca/Health-
502		Professionals-Site/Documents/Summary evidence COVID-19 testing guidance.pdf.
503	22.	Hogan CA, Jassem AN, Sbihi H, Joffres Y, Tyson JR, Noftall K, Taylor M, Lee T, Fjell
504		C, Wilmer A, Galbraith J, Romney MG, Henry B, Krajden M, Galanis E, Prystajecky N,
505		Hoang LMN. 2021. Rapid Increase in SARS-CoV-2 P.1 Lineage Leading to
506		Codominance with B.1.1.7 Lineage, British Columbia, Canada, January-April 2021.
507		Emerg Infect Dis 27:2802-2809.
508	23.	Government of Canada. 2022. COVID-19 vaccine: Canadian Immunization Guide.
509		https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-
510		immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html. Accessed
511		August 26 2022.

- 512 24. Tibshirani R. 1996. Regression shrinkage and selection via the Lasso. Journal of the
- 513 Royal Statistical Society Series B (Methodological) 58:267-88.
- 514 25. Lundberg S. LS. 2017. A unified approach to interpreting model predictions, abstr 31st
 515 Conference on Neural Information Processing Systems (NIPS 2017),

- 517 **Table 1.** Epidemiological, clinical and laboratory data of the cohort of asymptomatic individuals
- 518 tested during the test period of the study.
- 519

Group	Subgroup	Phase 3
	First positives	71642
Testing	SubgroupFirst positivesNegativesRepeatsRepeatsNPSGOtherOther10-45-1819-3940-5940-5960-7980+80+MaleFemaleUnknown112	252342
	Repeats	7801
	SubgroupFirst positivesNegativesNegativesRepeatsNPSGOtherOther0-45-1819-3940-5960-7960-7980+MaleFemaleUnknown123	35369
Specimen type		36108
		165
No <i>E</i> gene result		21068
	0-4	1963
	GroupSubgroupPhase 3First positives71642Negatives252342Repeats7801Repeats7801MP35369SG36108Other165gene result210680-419635-18916119-393191440-591986460-79745380+1279Male33415Female37653Unknown5741318412895133635	
		31914
Age (years)		19864
		7453
		1279
	Male	33415
Sex	5-18 9161 19-39 31914 40-59 19864 60-79 7453 80+ 1279 Male 33415 Female 37653 Unknown 574	
		574
	1	31841
Patient health authority	Other 165 0ther 165 21068 1963 5-18 9161 19-39 31914 40-59 19864 60-79 7453 80+ 1279 Male 33415 Female 37653 Unknown 574 1 31841 3 3635	8951
	3	3635

4		17202
	5	9752
	Unknown	261
	Unvaccinated	18459
Vaccination status**	4 17202 5 9752 Unknown 261 Unvaccinated 18459 1 dose 1540 Fully vaccinated 47580 Unknown 4063 Mapha 0 Beta 0 Delta 9049 Gamma 0 Omicron (BA.1) 12945 Unknown 28580	
		47580
		4063
	Alpha	0
	Beta	0
VoC lineage	Delta	9049
voc meage	Gamma	0
	Omicron (BA.1)	12945
	Unknown	28580

520 *For all group variables except testing, data presented as first positive result per person

521 **Does not include individuals who received ≥ 3 doses of vaccine

522

523 NP: nasopharyngeal; SG: saline gargle; VoC: variant of concern

524	Table 2.	SEIR a	and ML	model	comp	arisons	for	SARS	-CoV	-2	incidence	prediction
-----	----------	--------	--------	-------	------	---------	-----	------	------	----	-----------	------------

525

Мо	del	SEIR	ML		
Sampling type		Random sampling			
Number of COVID-po	sitive samples	Small (~30)	Large (>1000)		
Sampling frequency		Single/multiple snapshots	Daily snapshots		
Flexibility:	i) Modeling of Transmission	i) Fixed in time	i) Time-independent		
ii) Ability to add in multiple predictors		ii) Unable to incorporate multiple predictors	ii) Allows incorporation of various predictors and is flexible in their representation		
Scalability		Single outbreak setting	Population level		
Computational Comp	lexity*	Low	Low-moderate		
Predictive power requ	uirements	Good in single setting with well-mixed population and stable contact behavior/infection control	No requirements other than sufficient sample size for Ct summary statistics by snapshot		
Additional Sampling	Requirements	None	Ordered in time, restricted to fixed interval sampling		

⁵²⁶

* Relative computational complexity based on assumed sample size provided in scalability row

527 COVID-19: coronavirus disease 2019; SEIR: susceptible-exposed-infected-recovered; ML:

528 machine learning; Ct: cycle threshold

530

A.



531

533 B.



534 535

- 536 **Figure 1.** Overall design (A) and flowchart (B) of the study.
- 537 BC: British Columbia; E gene: Envelope gene; SARS-CoV-2: Nov: November; Rt: reproductive
- 538 number; SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2

Ct in the province in Phase 3

540 A.





544 **Figure 2.** Violin plots demonstrating the cycle threshold value distribution (A) and absolute

545 number of cases of confirmed SARS-CoV-2 infection (B) in British Columbia across different

546 time points of the study period.

547 Ct. e: Envelope (*E*) gene cycle threshold value; SARS-CoV-2: SARS-CoV-2: severe acute

548 respiratory syndrome coronavirus type 2



551

Figure 3. Boxplot representation of MSE scores across models on out-of-sample simulated cyclethreshold data.

- 554 LGBM: Light Gradient Boosting Model; MSE: Mean squared error; XGBM: eXtreme Gradient
- 555 Boosting Model, ML: Machine Learning



557

558

559 Figure 4. Overall population modeling findings. A multiple-cross section SEIR model was fitted 560 to the overall population-level data (I), and showed an incidence peak from December 27 2021 to 561 January 1 2022, which overlapped with the observed peak of reported cases in the province. The 562 Monte Carlo chain model-predicted incidence curve is represented (black lines), and was 563 overlaid with the reported number of confirmed SARS-CoV-2-positive (yellow bars) cases. 564 Violin plots of the viral kinetic parameters for the SEIR model are presented (II). Three unique 565 time horizons were chosen, each of which is depicted by a different color. The MCMC approach 566 searches over the viral kinetic parameters presented above, and is based on prior values 567 described separately (Supplemental Table 6). To align with the described Omicron viral 568 kinetics, the incubation period was fixed and set at three days, and the infectious viral kinetic

- 569 parameter was fixed. An upper bound of I_0 was set at 0.100. The fit to detectable cycle threshold
- 570 distribution and the fit to proportion variable are presented over different time points (A).
- 571
- 572 Ct: cycle threshold; SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2; SEIR:
- 573 susceptible-exposed-infected-recovered



10.0 9.5

9.0

8.5 ·

7.5

17

16 15

14-

13

200

574

0.20

0.15

o.io.

0.05

1.0

0.5

0.0

0.5

-1.0

tO

100

150

575 Figure 5. Long-term care facility outbreak investigation modeling findings. a multiple-cross
576 section SEIR model was fitted to the outbreak data (I), and showed a peak in incidence on the

viral peak

100 sampno

- 577 12th day of the outbreak which preceded by two days the observed peak at the outbreak facility.
- 578 The population included in this outbreak investigation was sampled at three pre-determined time
- 579 points (dashed red lines). The Monte Carlo chain model-predicted incidence curve is represented
- 580 by black lines, and was overlaid with the reported number of confirmed SARS-CoV-2-positive
- 581 cases in this outbreak setting (yellow bars). Violin plots of the viral kinetic parameters for the
- 582 SEIR model are also presented in the outbreak case study (II).
- 583
- 584 Ct: cycle threshold; SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2; SEIR:
- 585 susceptible-exposed-infected-recovered
- 586

587	Supplemental Table	1. Vaccinat	ion phase de	efinitions us	ed for the study
-----	--------------------	-------------	--------------	---------------	------------------

SARS- CoV-2 phase	Vaccination Phase*	Wave**	Target population
Phase 1	Phase 1	Waves 1, 2, 3 Dec 14 2020 - Mar 7 2021	Residents, staff and essential visitors to long-term care settings; individuals assessed and awaiting a long-term care placement; health care workers providing care for COVID-19 patients; and remote and isolated Indigenous communities.
	Phase 2	3 Mar 8 2021 - Apr 2021	Individuals age ≥80; Indigenous peoples age ≥65 and Indigenous Elders; Indigenous communities; hospital staff, community general practitioners and medical specialists; vulnerable populations in select congregate settings; and staff in community home support and nursing services for seniors.
	Phase 3	3 Apr 15 2021 - May 10 2021	Individuals aged 60-79 years, Indigenous peoples aged 18-64 and people aged 16-74 who are clinically extremely vulnerable.
Phase 2.1	Phase 4	Waves 3, 4 May 11 2021- Jul 17 2021	Everyone aged ≥12 years-old. From September 2021, third vaccine dose available for people who are clinically extremely vulnerable
Phase 2.2	Phase 4	4 Jul 18 2021 - Nov 18 2021	
Phase 3*	Phase 5	4 Nov 19 2021 - Jan 8 2022	Everyone aged ≥5 years-old. From the end of November 2021, children aged 5-11 are eligible for vaccination. Everyone aged ≥18 and invited to get a 'booster' (third vaccine dose) within 6-8 months after receipt of their second dose.

588 *The current study included Phase 3 only

⁵⁸⁹ **Vaccination phases were defined by vaccine eligibility of the target populations in BC, and are

590 detailed separately (21)

591

592 SARS-CoV-2: SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2

- 593 Supplemental Table 2. SARS-CoV-2 diagnostic testing strategy based on the envelope (E) gene target and test result interpretation
- 594 criteria used for the participating laboratories

Type of assay	Assay used (manufacturer)	Extraction	PCR	Ct Interpretation
				criteria
		MagMax	ABI	Ct threshold for
Laboratory-developed	BCCDC PHL LDT		7500	positivity: 38
Laboratory-developed		MagNa	ABI	
		Pure 24	7500	
	LightMix SarbecoV E-gene plus EAV control	MagNA	LightCyc	
	assay (TIB Molbiol)	Pure	ler 480	Manufacturer
		Compact or		recommended
		MagNA		threshold
		Pure 96		
Commorcial	Allplex SARS-CoV-2 assay (Seegene)	STARlet	CFX 96	
Commercial				
	Cobas 6800 and 8800 SARS-CoV-2 Test (Roche			
	Xpert Xpress SARS-CoV-2 (Cepheid)			
	BD MAX SARS-CoV-2 (BD)			
	Respiratory Panel 2.1 (BioFire)			
	Panther Fusion (Hologic)			

595

596 BCCDC PHL: British Columbia Centre for Disease Control Public Health Laboratory; Ct: cycle threshold; FHA: Fraser Health

597 Authority; IHA: Interior Health Authority; LDT: laboratory-developed test; NHA: Northern Health Authority; PCR: polymerase chain

reaction; SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2; SPH: St. Paul's Hospital; VCH: Vancouver Coastal

599 Health.

Group	Subgroup	Phase 1 (Dec 14 2020 - May 10 2021)	Phase 2.1 (May 11 2021 - July 17 2021)	Phase 2.2 (July 18 2021 - Nov 18 2021)
	Positives	55291	6529	31613
Testing	Negatives	815993	190679	599953
	Repeats	53740	5263	18758
No <i>E</i> gene Result		1623	257	1611
	0-4	4203	712	3200
	5-18	23586 2849		12866
1.00	19-39	15437	1709	8173
Age	40-59	7950	821	4366
	60-79	2150	181	1391
	80+	6183	2312	47
	Male	29102	3492	16357
Ser	Female	25729	2969	14573
	Unknown	460	68	683

Supplemental Table 3. Epidemiological, clinical and laboratory data of the earlier British Columbia SARS-CoV-2 pandemic phases

	1	31045	3387	7851
	2	4233	987	9761
Patient health authority	3	1922	275	4317
	4	337	45	230
	5	15370	1680	6065
	Unknown	2384	155	2389
Vaccination	1 dose	100	99	9665
status	Fully vaccinated	16293	2462	16174
	Alpha	74	10	0
	Beta	253	483	22220
VoC lineage	Delta	4595	2134	99
	Gamma	0	0	0
	Omicron	293	39	307

02 VoC: variant of concern

Hyperparameter	Lasso	RF	LGBM	XGBoost	Catboost
Alpha	[0.001,0.01,0.1]	-	-	-	-
Max Depth	-	[2,4,8,16,32]	[2,4,8]	[6,10]	-
Number of Estimators	-	[4,16,64,256]	-	-	-
Minimum Sample Split	-	[2,4,8,16,32]	-	-	-
Number of Leaves	-	-	[4,8,16,32,6 4,128]	-	-
Minimum Data in Leaf	-	-	[2,4,8,16,32]	-	-
Depth	-	-	-	-	[1,5,10]
Iterations	[500,1000,2000]	-	-	-	[250,500,10 00]
Learning Rate	-	-	-	-	[0,001, 0.01, 0.1]
L2 Regularization	-	-	-	-	[1,5,10]
Min child weight	-	-	-	[1,3]	-

603 Supplemental Table 5. Hyperparameter selection

604

606 Boosting Model

⁶⁰⁵ RF: Random Forest; LGBM: Light Gradient Boosting Model; XGBM: eXtreme Gradient

608 Supplemental Table 6. Control table of priors for SEIR model

Values	Names*	Fixed	Lower bound	Upper bound	Steps	Lower start	Upper start
0	tshift	1	0	3	0.1	0	10
5	desired_mode	1	0	7	0.1	0	10
19.73	viral_peak	0	0	40	0.1	15	25
5	obs_sd	0	0	25	0.1	1	10
0.79	sd_mod	1	0	1	0.1	0.4	0.6
14	sd_mod_wane	1	0	14	0.1	0	14
40	true_0	1	40	100	0.1	40	100
40	intercept	1	35	100	0.1	35	100
3	LOD	1	0	10	0.1	0	10
5	incu	1	0	10	0.1	0	10
13.29	t_switch	0	0	30	0.1	10	30
38	level_switch	0	0	40	0.1	33	40
1000	wane_rate2	1	0	10000	0.1	10	50
0.103	prob_detect	0	0	1	0.1	0.01	0.1
1	t_unit	1	0	1	0.1	0	1
2	RO	0	1	10	0.1	1.5	3
4	infectious	1	0	25	0.1	5	10
3	incubation	1	0	25	0.1	5	10
1	tO	1	0	100	0.1	0	50
0.0001	10	0	0	0.1	0.1	0	0.001

609 *Adapted parameters (3)

610

611 SEIR: susceptible-exposed-infected-recovered







616 for saline gargle compared to nasopharyngeal specimens for the entire study period.

617 Ct. e: Envelope (*E*) gene cycle threshold value; NP: nasopharyngeal

618

619

621



623 Supplemental Figure 2. Twenty most prevalent SARS-CoV-2 variant of concern lineages in

- 624 British Columbia from January 2021 to January 2022. The current study was performed during a
- time of Omicron variant predominance, from November19 2021 to January 8 2022.
- 626 BCCDC: British Columbia Centre for Disease Control; SARS-CoV-2: severe acute respiratory
- 627 syndrome coronavirus type 2

628

medRxiv preprint doi: https://doi.org/10.1101/2023.03.06.23286837; this version posted March 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



630

631 Supplemental Figure 3. Vaccination status definitions. Vaccination status was defined based on 632 the date of vaccine receipt relative to the date of the sample collection included for the study. For 633 the Janssen vaccine only, fully vaccinated status was defined as having received one dose 14 634 days or more prior to sample collection. For all other vaccines, Unvaccinated status was defined 635 as having received no SARS-CoV-2 vaccine, or having received a SARS-CoV-2 vaccine less 636 than 21 days prior to the sample collection date. **Partially vaccinated** status was defined as 637 having received the SARS-CoV-2 vaccine dose 1 greater or equal to 21 days prior to sample 638 collection, but having received dose 2 less than 14 days prior to the sample collection. Fully 639 vaccinated status was defined as greater or equal to 14 days since the receipt of dose 2, but 640 having received dose 3 less than 14 days prior to the sample collection. 641



644 A.

	Residents (n=93)	Staff (<i>n</i> =63)
Age (Median, range)	89 (46-100)	42 (19-71)
Female (%)	68 (73.1%)	54 (85.7%)
Asymptomatic at the time of assessment (%)	54 (58.1%)	6 (9.5%)
Ever hospitalized	3 (3.2%)	0
Deceased	26 (28.0%)	0

645

646 B.



647





651

652 Supplemental Figure 5. SHAP summary outputs explaining the machine learning output based653 on simulated cycle threshold (Ct) data. Results are presented stratified by three different

654 population sizes: 100, 1,000 and 10,000 with each column in descending order of performance.

- 655 Of the five features explored, the top ranking feature across all models was the variance of the Ct
- 656 data.

657 SHAP: SHapley Additive exPlanations; LGBM: Light Gradient Boosting Model; XGBM:

658 eXtreme Gradient Boosting Model

659